

AN OVERVIEW OF THE GROWTH OF THE INDIAN PHARMACEUTICAL INDUSTRY

Shiv Murti Singh

Research Scholar

Pharmacy

Asian International University Imphal, Manipur

Abstract

In recent decades, the pharmaceutical business in India has experienced extraordinary expansion and transformation, emerging as a global leader in healthcare. Post-independence policies emphasising public health and self-sufficiency initially shaped the industry, but it has since transformed into a vibrant ecosystem distinguished by innovation and strategic collaborations. India is the world's third-largest manufacturer of pharmaceuticals by volume, thanks to its sizable domestic market, highly skilled labour force, and advantageous regulatory framework. With its focus on R&D and proficiency in the production of generic drugs, it has been known as the "pharmacy of the world." Its incorporation into international supply chains has been made easier by increased investments in infrastructure, technology, and human resources. Innovation and a dedication to global healthcare are what drive the industry's persistence in the face of obstacles including intellectual property rights and regulatory compliance. This summary clarifies the state of the Indian pharmaceutical industry, highlighting its importance as a major driver of both economic growth and world health.

Keywords: *Indian pharmaceutical industry, global pharmaceutical industry, value, volume, Annual Growth Rate.*

1. INTRODUCTION

According to Equity Master, the pharmaceutical market in India is the thirteenth largest in terms of value and the third largest in terms of volume worldwide. Significantly, India is the world's top supplier of generic medications; by volume, its generics make up a healthy 20% of all exports. The Indian pharmaceutical sector has always been extremely fragmented, but in recent years, consolidation has become a noticeable trend.

India is strategically set up to lead the pharmaceutical industry globally in light of the fact that to a major pool of profoundly gifted researchers and designers. The way that Indian

Exploring Innovation Research Methodologies in a Variety of Multidisciplinary Fields and Their Prospective Future Impact February 2024

pharmaceutical organizations supply over 80% of the antiretroviral prescriptions used to treat HIV globally is a striking landmark to India's responsibility. India's position has been additionally set by the UN-upheld Prescriptions Patent Pool, which has inked six sub-licenses with notable Indian pharmaceutical firms, including Aurobindo, Cipla, Desano, Emcure, Hetero Labs, and Laurus Labs. These sublicences empower these organizations to deliver Tenofovir Alafenamide (TAF), a conventional enemy of HIV drug, for 112 immature countries. This demonstrates India's basic situation in global medical services and its commitment to giving individuals in need admittance to sensibly estimated prescription.

2. LITERATURE REVIEW

Lakdawalla et.al (2018). work delves into the intricate economics of the pharmaceutical sector, a crucial aspect in understanding the industry's dynamics. By examining various economic principles, Lakdawalla sheds light on how market forces, regulatory frameworks, and innovation incentives shape the pharmaceutical landscape.

González et.al (2021). This study, conducted by González Peña et al., explores the relationship between pharmaceutical research on water and wastewater and market dynamics, consumption trends, and disease incidence. The paper likely investigates whether the focus of pharmaceutical research in this domain aligns with market demands and health priorities.

Nirmala et.al (2018). work explores the utilization of bamboo as a source of natural antioxidants and its applications in the food and pharmaceutical sectors. The paper likely discusses the chemical composition of bamboo, its antioxidant properties, and potential applications in food preservation and pharmaceutical formulations.

3. INDIAN PHARMACEUTICAL INDUSTRY

With analysts predicting an accelerated growth of 15 to 20% CAGR over the next ten years, the Indian pharmaceutical business is expected to develop significantly and reach between US\$49 billion and US\$74 billion by 2023. Dynamic changes are occurring in this industry, such as the creation of special economic zones (SEZs), greater investments from domestic and foreign players, wider penetration of the rural market, and significant acquisitions by multinational corporations.

With more inventive R&D, Indian pharmaceutical businesses are becoming important outsourcing partners for their international counterparts. These companies are firmly

Exploring Innovation Research Methodologies in a Variety of Multidisciplinary Fields and Their Prospective Future Impact February 2024

establishing themselves as competitors in manufacturing and research and development, as well as possible partners in other domains, inside the global pharmaceutical value chain. The pharmaceutical sector worldwide is confronted with dynamic social, demographic, and economic environments, which include demands for lower drug costs and outcome-based pricing. The Indian pharmaceutical business is growing at a solid rate despite obstacles including reduced R&D productivity and more stringent regulations. By 2020, the local market is expected to grow at a compound annual growth rate (CAGR) of 15% to 20% and reach a valuation of between US\$50 billion and US\$74 billion.

4. GOVERNMENT INITIATIVES

- To work on the framework and medication guideline framework, the Indian government intends to work around eight little medication testing labs at significant ports and air terminals. By observing the norms of pharmaceuticals that are imported and sent out, this activity looks to eliminate how much time that is spent on quality assessment.
- On account of the public authority's choice to allow half open subsidizing in the pharmaceutical area through the Public Confidential Organization (PPP) model, India is supposed to be among the main five global focal points for pharmaceutical development by 2020.
- To assess and analyse the type of Indian pharmaceutical organizations to those of their global partners, the Indian Pharmaceutical Affiliation (IPA) plans to foster information honesty standards.
- The public authority means to give motivating forces to state-run and business mass drug creators to work with the 'Make in India' drive and diminish reliance on imports of Dynamic Pharmaceutical Fixings (Programming interface), of which around 85% come from China.
- An interministerial coordination panel was shaped by the Division of Pharmaceuticals to survey, direction, and manage issues that Indian pharmaceutical organizations experience consistently.
- Moreover, the Branch of Pharmaceuticals intends to lay out an investment store with a capital of Rs. 1,000 crore (US\$149.11 million) to help business visionaries chipping away at Research and development in the biotech and pharmaceutical areas.

5. GROWTH OF INDIA PHARMACEUTICAL INDUSTRY

Exploring Innovation Research Methodologies in a Variety of Multidisciplinary Fields and Their Prospective Future Impact February 2024

With 10% of the industry's volume and 2.4% of its value, the Indian pharmaceutical industry is one of the biggest on the planet. Figures demonstrate that the area would develop at a Build Annual Growth Rate (CAGR) of 15.92%, from US\$20 billion of every 2015 to US\$55 billion by 2020. Conventional drugs make up the biggest gathering, with a 71% piece of the pie. India is supposed to ascend to the third position on the planet's conventional Dynamic Pharmaceutical Fixing (Programming interface) trader market by 2016. Besides, India beat the US in the quantity of utilizations for Medication Expert Records (DMFs) and is second in Condensed New Medication Applications (ANDAs). Indian pharmaceuticals are offered to in excess of 200 nations, with the US being a significant objective. By volume, nonexclusive medications make up 20% of all commodities from India. Pharmaceutical commodities are supposed to outperform US\$25 billion out of 2015, as indicated by the Pharmaceuticals Products Advancement Committee (Pharmexcil). Among the proportions of the Indian government is an investment asset of US\$640 million, which is planned to help drug research and reinforce the pharmaceutical foundation. Under the 'Pharma Vision 2020' program, India desires to set up a good foundation for itself as a main place for start to finish drug disclosure, mirroring its goals for the pharmaceutical industry around the world.

❖ **Increasing investments in the sector**

- The Indian pharmaceutical market extended fundamentally, ascending from US\$6 billion of every 2005 to a Build Annual Growth Rate (CAGR) of 17.46% in 2015.
- Extra growth is anticipated, with a build annual growth rate of 15.92%, arriving at US\$55 billion by 2020.
- India is anticipated to rank 6th in outright terms and be among the main three pharmaceutical business sectors on the planet by 2020 regarding steady growth.
- India enjoys a cutthroat upper hand over other pharmaceutical business sectors because of its a lot of lower creation costs contrasted with the US and almost 50% of Europe.

❖ **Generic drugs form the largest segment**

- At 70% of the Indian pharmaceutical market as far as deals, nonexclusive meds address the biggest piece of the industry.
- India has turned into the world's biggest provider of nonexclusive meds, representing 20% of the market's volume trades, and is supposed to keep filling from here on out.

Exploring Innovation Research Methodologies in a Variety of Multidisciplinary Fields and Their Prospective Future Impact

February 2024

- Of the US\$20 billion in by and large market incomes, protected drugs and over-the-counter (OTC) meds represent 21% and 9%, separately.

6. CONCLUSION

Important data from the study about the pharmaceutical sector showed that, with a 41.17% coefficient of variance, the mean value of exports was 6619.33. In a similar vein, the average import value was 1090.29, with a 43.26% coefficient of variance. The industry's exports' Annual Growth Rate (AGR) was examined in the study, and its growth trajectory was given weight. Nonetheless, over the study period, the total export and import statistics of the Indian pharmaceutical industry did not show any appreciable fluctuations, indicating a steady trend in the trade dynamics within the business.

REFERENCES

1. Belkhir, L., & Elmeligi, A. (2019). *Carbon footprint of the global pharmaceutical industry and relative impact of its major players. Journal of Cleaner Production, 214, 185-194.*
2. Chowdhury, L. A. M., Rana, T., & Azim, M. I. (2019). *Intellectual capital efficiency and organisational performance: In the context of the pharmaceutical industry in Bangladesh. Journal of Intellectual Capital, 20(6), 784-806.*
3. González Peña, O. I., López Zavala, M. Á., & Cabral Ruelas, H. (2021). *Pharmaceuticals market, consumption trends and disease incidence are not driving the pharmaceutical research on water and wastewater. International journal of environmental research and public health, 18(5), 2532.*
4. Hilfiker, R., & Von Raumer, M. (Eds.). (2019). *Polymorphism in the Pharmaceutical Industry: Solid Form and Drug Development. John Wiley & Sons.*
5. Lakdawalla, D. N. (2018). *Economics of the pharmaceutical industry. Journal of Economic Literature, 56(2), 397-449.*
6. Nirmala, C., Bisht, M. S., Bajwa, H. K., & Santosh, O. (2018). *Bamboo: A rich source of natural antioxidants and its applications in the food and pharmaceutical industry. Trends in Food Science & Technology, 77, 91-99.*

Exploring Innovation Research Methodologies in a Variety of
Multidisciplinary Fields and Their Prospective Future Impact
February 2024

7. Osorio, L. L. D. R., Flórez-López, E., & Grande-Tovar, C. D. (2021). *The potential of selected agri-food loss and waste to contribute to a circular economy: Applications in the food, cosmetic and pharmaceutical industries. Molecules, 26(2), 515.*
8. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). *Artificial intelligence in drug discovery and development. Drug discovery today, 26(1), 80.*
9. Prasad, M., Lambe, U. P., Brar, B., Shah, I., Manimegalai, J., Ranjan, K., ... & Prasad, G. (2018). *Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomedicine & Pharmacotherapy, 97, 1521-1537.*
10. Taneja, N., & Sharma, M. (2019). *Antimicrobial resistance in the environment: The Indian scenario. Indian Journal of Medical Research, 149(2), 119-128.*
